GREENWICH LIFESCIENCES INC (GLSI)
Health Care · Cancer immunotherapy / breast cancer · NASDAQ
Greenwich LifeSciences develops GLSI-100, an immunotherapy combining a HER2/neu-targeting peptide and GM-CSF to prevent breast cancer recurrence after surgery.
What GREENWICH LIFESCIENCES INC does
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy designed to prevent recurrence of breast cancer in patients with residual disease or high-risk pathologic complete response following surgery. The drug combines GP2 (a HER2/neu transmembrane peptide that elicits a targeted immune response) with GM-CSF (an FDA-approved immunoadjuvant). The company is currently conducting the Phase III Flamingo-01 trial and expanding it globally with up to 150 planned sites, including sites in Europe. The company has no revenue, negative cash flow, and substantial going concern doubts but has been raising capital through equity offerings.
Themes: ["Breast cancer immunotherapy","HER2/neu-targeted therapy","Cancer recurrence prevention","Personalized cancer immunotherapy"]
Fundamentals
- Price$19.57 as of 2026-07-09 close
- Market cap$288M as of 2026-07-10
- 1-year return+87.0% as of 2026-07-09 close
- ROE-941.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.43 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Phase III trial (Flamingo-01) may not achieve primary efficacy endpoints required for regulatory approval","Going concern risk: Company has cumulative losses of $92.8M, negative operating cash flows, zero revenue, and substantial doubt about ability to continue operations within one year without additional capital","Supply chain dependency: Exclusive reliance on single manufacturer for GM-CSF component; component only FDA-approved in US and availability in other countries subject to regulatory uncertainty"]
Competitors & peers
- Roche/Genentech (HER2-targeted therapies including Herceptin)
- Pfizer (HER2-directed therapies)
- AstraZeneca (breast cancer immunotherapies)
- Merck (cancer immunotherapy platform)
- Bristol Myers Squibb (checkpoint inhibitors and cancer immunotherapy)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.